Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 12/20 | 0.58 |
| ▸ | PPARA | Q07869 | 8/20 | 0.58 |
| ▸ | PPARG | P37231 | 5/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552975 | 0.90 | PPARD (0.59) | PPARDPPARAPPARGFFAR1TP53 | |
| SCHEMBL3851691 | 0.85 | PPARD (0.48) | PPARDPPARAPPARGFFAR1ALDH1A1 | |
| SCHEMBL1553680 | 0.84 | PPARD (0.47) | PPARDPPARAPPARGFFAR1ALDH1A1 | |
| SCHEMBL3537625 | 0.81 | PPARD (0.49) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL1553871 | 0.79 | PPARD (0.48) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL27651021 | 0.79 | PPARD (0.51) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL14039526 | 0.79 | PPARD (0.62) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL1554172 | 0.78 | NPC1 (0.44) | PPARDPPARAPPARGFFAR1ALDH1A1 | |
| SCHEMBL1554504 | 0.78 | PPARD (0.49) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5516102 | 0.78 | PPARD (0.77) | PPARDPPARAPPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735303-B1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMA INC (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1735303-B1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMA INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-7576109-B2 | 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576109-B2 | 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576109-B2 | 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070060626-A1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060626-A1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060626-A1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060626-A1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.